Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 837 Views
-
Last post by NHE
-
- 0 Replies
- 2472 Views
-
Last post by frodo
-
- 0 Replies
- 1124 Views
-
Last post by NHE
-
- 1 Replies
- 1122 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1412 Views
-
Last post by frodo
-
- 0 Replies
- 1670 Views
-
Last post by NHE
-
- 0 Replies
- 2203 Views
-
Last post by vesta
-
- 0 Replies
- 1656 Views
-
Last post by frodo
-
- 0 Replies
- 2293 Views
-
Last post by DIM